SCHEMBL5409691

SCHEMBL5409691

O=C(NS(=O)(=O)/C=C/c1ccc(C(F)(F)F)cc1)c1ccc(F)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 8/20 0.51
FLT1 P17948 2/20 0.44
FLT4 P35916 2/20 0.44
KDR P35968 2/20 0.44
MAOB P27338 2/20 0.42
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
HPGD P15428 1/20 0.41
AHR P35869 1/20 0.41
PYGL P06737 2/20 0.40
HDAC3 O15379 1/20 0.39
ADAM17 P78536 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5409699 1.00 PTGES2 (0.51) PTGES2FLT1FLT4KDRMAOB
SCHEMBL4619554 0.90 FLT1 (0.50) FLT1FLT4KDRAHR
SCHEMBL4619560 0.90 FLT1 (0.50) FLT1FLT4KDRAHR
SCHEMBL5411563 0.88 FLT1 (0.53) PTGES2FLT1FLT4KDRMAOB
SCHEMBL5411552 0.88 FLT1 (0.53) PTGES2FLT1FLT4KDRMAOB
SCHEMBL5411637 0.88 FLT1 (0.48) PTGES2FLT1FLT4KDRAHR
SCHEMBL5411653 0.88 FLT1 (0.48) PTGES2FLT1FLT4KDRAHR
SCHEMBL5418925 0.87 PTGES2 (0.52) PTGES2FLT1FLT4KDRMAOB
SCHEMBL5418917 0.87 PTGES2 (0.52) PTGES2FLT1FLT4KDRMAOB
SCHEMBL5414818 0.86 PTGES2 (0.54) PTGES2MAOBCYP1A1CYP1B1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 PTGES2 3551/4885FLT1 4126/4885FLT4 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.